Cargando…

Colchicine for Prevention of Atrial Fibrillation after Cardiac Surgery in the Early Postoperative Period

Background. Postoperative atrial fibrillation (POAF) is a common complication of cardiac surgery. It has been proven to be associated with an increase in the incidence of early complications and mortality, an increase in the rate of hospital stay duration, and economic costs of their treatment. One...

Descripción completa

Detalles Bibliográficos
Autores principales: Shvartz, Vladimir, Le, Tatyana, Kryukov, Yuri, Sokolskaya, Maria, Ispiryan, Artak, Khugaeva, Eleonora, Yurkulieva, Gulsuna, Shvartz, Elena, Petrosyan, Andrey, Bockeria, Leo, Bockeria, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911341/
https://www.ncbi.nlm.nih.gov/pubmed/35268478
http://dx.doi.org/10.3390/jcm11051387
_version_ 1784666775742316544
author Shvartz, Vladimir
Le, Tatyana
Kryukov, Yuri
Sokolskaya, Maria
Ispiryan, Artak
Khugaeva, Eleonora
Yurkulieva, Gulsuna
Shvartz, Elena
Petrosyan, Andrey
Bockeria, Leo
Bockeria, Olga
author_facet Shvartz, Vladimir
Le, Tatyana
Kryukov, Yuri
Sokolskaya, Maria
Ispiryan, Artak
Khugaeva, Eleonora
Yurkulieva, Gulsuna
Shvartz, Elena
Petrosyan, Andrey
Bockeria, Leo
Bockeria, Olga
author_sort Shvartz, Vladimir
collection PubMed
description Background. Postoperative atrial fibrillation (POAF) is a common complication of cardiac surgery. It has been proven to be associated with an increase in the incidence of early complications and mortality, an increase in the rate of hospital stay duration, and economic costs of their treatment. One of the pharmaceutical drugs recommended by the American College of Cardiology (ACC)/American Heart Association (AHA) for preventing POAF is colchicine (class IIB). However, the results of research on the efficacy and safety of colchicine are ambiguous and, consequently, require further study. Objective. Evaluating the efficacy of short-term colchicine administration in the prevention of POAF in patients after open-heart surgery. Materials and methods. Double-blind, randomized, placebo-controlled clinical trial. The subjects were randomly assigned to two groups: treatment group (n = 50) with subjects receiving 1 mg of colchicine 24 h before the surgery, as well as on days 2, 3, 4, and 5 in the postoperative period; and the control group (n = 51), receiving placebo on the same schedule. The primary endpoint was the frequency of POAF in both groups within 7 days after surgery. Results. The study included 101 patients (82 men, 19 women). Baseline clinical, laboratory, instrumental, and intraoperative data did not differ statistically significantly between the groups. POAF was detected in 9 patients (18%) of the treatment group and 15 subjects (29.4%) of the control group, which had no statistical significance (odds ratio, OR 0.527; 95% Cl 0.206–1.349; p = 0.178). No statistically significant differences were revealed for most secondary endpoints, as well as between the groups for all laboratory parameters. There were statistically significant differences between the groups solely in the frequency of diarrhea: 16 (32%) patients in the treatment group and 6 (11.8%) subjects in the control group (OR 3.529; 95% Cl 1.249–9.972; p = 0.010). Conclusions. We did not detect any statistical differences between the groups in terms of primary endpoints, which could be due to the insufficient volume of the sample of the study. However, we detected some trends of statistical differences among the groups in terms of some parameters. Clinical Trials Registration. ClinicalTrials. Unique identifier: NCT04224545.
format Online
Article
Text
id pubmed-8911341
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89113412022-03-11 Colchicine for Prevention of Atrial Fibrillation after Cardiac Surgery in the Early Postoperative Period Shvartz, Vladimir Le, Tatyana Kryukov, Yuri Sokolskaya, Maria Ispiryan, Artak Khugaeva, Eleonora Yurkulieva, Gulsuna Shvartz, Elena Petrosyan, Andrey Bockeria, Leo Bockeria, Olga J Clin Med Article Background. Postoperative atrial fibrillation (POAF) is a common complication of cardiac surgery. It has been proven to be associated with an increase in the incidence of early complications and mortality, an increase in the rate of hospital stay duration, and economic costs of their treatment. One of the pharmaceutical drugs recommended by the American College of Cardiology (ACC)/American Heart Association (AHA) for preventing POAF is colchicine (class IIB). However, the results of research on the efficacy and safety of colchicine are ambiguous and, consequently, require further study. Objective. Evaluating the efficacy of short-term colchicine administration in the prevention of POAF in patients after open-heart surgery. Materials and methods. Double-blind, randomized, placebo-controlled clinical trial. The subjects were randomly assigned to two groups: treatment group (n = 50) with subjects receiving 1 mg of colchicine 24 h before the surgery, as well as on days 2, 3, 4, and 5 in the postoperative period; and the control group (n = 51), receiving placebo on the same schedule. The primary endpoint was the frequency of POAF in both groups within 7 days after surgery. Results. The study included 101 patients (82 men, 19 women). Baseline clinical, laboratory, instrumental, and intraoperative data did not differ statistically significantly between the groups. POAF was detected in 9 patients (18%) of the treatment group and 15 subjects (29.4%) of the control group, which had no statistical significance (odds ratio, OR 0.527; 95% Cl 0.206–1.349; p = 0.178). No statistically significant differences were revealed for most secondary endpoints, as well as between the groups for all laboratory parameters. There were statistically significant differences between the groups solely in the frequency of diarrhea: 16 (32%) patients in the treatment group and 6 (11.8%) subjects in the control group (OR 3.529; 95% Cl 1.249–9.972; p = 0.010). Conclusions. We did not detect any statistical differences between the groups in terms of primary endpoints, which could be due to the insufficient volume of the sample of the study. However, we detected some trends of statistical differences among the groups in terms of some parameters. Clinical Trials Registration. ClinicalTrials. Unique identifier: NCT04224545. MDPI 2022-03-03 /pmc/articles/PMC8911341/ /pubmed/35268478 http://dx.doi.org/10.3390/jcm11051387 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shvartz, Vladimir
Le, Tatyana
Kryukov, Yuri
Sokolskaya, Maria
Ispiryan, Artak
Khugaeva, Eleonora
Yurkulieva, Gulsuna
Shvartz, Elena
Petrosyan, Andrey
Bockeria, Leo
Bockeria, Olga
Colchicine for Prevention of Atrial Fibrillation after Cardiac Surgery in the Early Postoperative Period
title Colchicine for Prevention of Atrial Fibrillation after Cardiac Surgery in the Early Postoperative Period
title_full Colchicine for Prevention of Atrial Fibrillation after Cardiac Surgery in the Early Postoperative Period
title_fullStr Colchicine for Prevention of Atrial Fibrillation after Cardiac Surgery in the Early Postoperative Period
title_full_unstemmed Colchicine for Prevention of Atrial Fibrillation after Cardiac Surgery in the Early Postoperative Period
title_short Colchicine for Prevention of Atrial Fibrillation after Cardiac Surgery in the Early Postoperative Period
title_sort colchicine for prevention of atrial fibrillation after cardiac surgery in the early postoperative period
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911341/
https://www.ncbi.nlm.nih.gov/pubmed/35268478
http://dx.doi.org/10.3390/jcm11051387
work_keys_str_mv AT shvartzvladimir colchicineforpreventionofatrialfibrillationaftercardiacsurgeryintheearlypostoperativeperiod
AT letatyana colchicineforpreventionofatrialfibrillationaftercardiacsurgeryintheearlypostoperativeperiod
AT kryukovyuri colchicineforpreventionofatrialfibrillationaftercardiacsurgeryintheearlypostoperativeperiod
AT sokolskayamaria colchicineforpreventionofatrialfibrillationaftercardiacsurgeryintheearlypostoperativeperiod
AT ispiryanartak colchicineforpreventionofatrialfibrillationaftercardiacsurgeryintheearlypostoperativeperiod
AT khugaevaeleonora colchicineforpreventionofatrialfibrillationaftercardiacsurgeryintheearlypostoperativeperiod
AT yurkulievagulsuna colchicineforpreventionofatrialfibrillationaftercardiacsurgeryintheearlypostoperativeperiod
AT shvartzelena colchicineforpreventionofatrialfibrillationaftercardiacsurgeryintheearlypostoperativeperiod
AT petrosyanandrey colchicineforpreventionofatrialfibrillationaftercardiacsurgeryintheearlypostoperativeperiod
AT bockerialeo colchicineforpreventionofatrialfibrillationaftercardiacsurgeryintheearlypostoperativeperiod
AT bockeriaolga colchicineforpreventionofatrialfibrillationaftercardiacsurgeryintheearlypostoperativeperiod